PubRank

FITMI - First In Treating Male Infertility

Clinical Trial ID NCT05212337

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT05212337

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998 17.76
2 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 15.96
3 International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod 2007 6.08
4 Minireview: the OPG/RANKL/RANK system. Endocrinology 2001 4.47
5 Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2007 2.82
6 Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 2012 2.34
7 Male infertility: pathogenesis and clinical diagnosis. Best Pract Res Clin Endocrinol Metab 2011 1.51
8 Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2011 1.27
9 Infertility in the third millennium: implications for the individual, family and society: condensed meeting report from the Bertarelli Foundation's second global conference. Hum Reprod Update 2004 1.12
10 Vitamin D is necessary for reproductive functions of the male rat. J Nutr 1989 1.07
11 Selected genetic factors associated with male infertility. Hum Reprod Update 2002 1.04
12 Male Reproductive Disorders and Fertility Trends: Influences of Environment and Genetic Susceptibility. Physiol Rev 2016 0.96
13 Vitamin D and male reproduction. Nat Rev Endocrinol 2014 0.96
14 Reproductive toxicity of denosumab in cynomolgus monkeys. Reprod Toxicol 2013 0.95
15 Normalization of serum calcium restores fertility in vitamin D-deficient male rats. J Nutr 1992 0.89
16 Denosumab treatment for juvenile Paget's disease: results from two adult patients with osteoprotegerin deficiency ("Balkan" mutation in the TNFRSF11B gene). J Clin Endocrinol Metab 2014 0.89
17 Paget's disease of the bone after treatment with Denosumab: a case report. Bone 2012 0.85
18 Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. Clin Endocrinol (Oxf) 2013 0.85
19 Vitamin D metabolism and effects on pluripotency genes and cell differentiation in testicular germ cell tumors in vitro and in vivo. Neoplasia 2012 0.83
20 RANKL inhibition for the management of patients with benign metabolic bone disorders. Expert Opin Investig Drugs 2009 0.82
21 Influence of vitamin D on cisplatin sensitivity in testicular germ cell cancer-derived cell lines and in a NTera2 xenograft model. J Steroid Biochem Mol Biol 2012 0.82
22 An open-label study in healthy men to evaluate the risk of seminal fluid transmission of denosumab to pregnant partners. Br J Clin Pharmacol 2015 0.81
23 Characterization of the testicular, epididymal and endocrine phenotypes in the Leuven Vdr-deficient mouse model: targeting estrogen signalling. Mol Cell Endocrinol 2013 0.80
24 Clinical utility of denosumab for treatment of bone loss in men and women. Clin Interv Aging 2011 0.79
25 Effects of vitamin D supplementation on semen quality, reproductive hormones and live birth rate: a randomized clinical trial. J Clin Endocrinol Metab 2017 0.75
Next 100